Evidence map›Paper›PMID 38542325›Full record

ArticleInternational journal of molecular sciences2024

Low-Dose Sorafenib Promotes Cancer Stem Cell Expansion and Accelerated Tumor Progression in Soft Tissue Sarcomas.

Sylvia M Cruz, Khurshid R Iranpur, Sean J Judge, Erik Ames, Ian R Sturgill, Lauren E Farley, Morgan A Darrow, Jiwon Sarah Crowley, Arta M Monjazeb, William J Murphy and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Sylvia M CruzDivision of Surgical Oncology, Department of Surgery, University of California Davis, Sacramento, CA 95817, USA.ORCID 0000-0001-9007-6639
Khurshid R IranpurDivision of Surgical Oncology, Department of Surgery, University of California Davis, Sacramento, CA 95817, USA.
Sean J JudgeDivision of Surgical Oncology, Department of Surgery, University of California Davis, Sacramento, CA 95817, USA.
Erik AmesDepartment of Pathology, Stanford University, Stanford, CA 94305, USA.
Ian R SturgillBioinformatics and Computational Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Lauren E FarleyDivision of Surgical Oncology, Department of Surgery, University of California Davis, Sacramento, CA 95817, USA.
Morgan A DarrowDepartment of Pathology and Laboratory Medicine, University of California Davis, Sacramento, CA 95817, USA.
Jiwon Sarah CrowleyDivision of Surgical Oncology, Department of Surgery, University of California Davis, Sacramento, CA 95817, USA.
Arta M MonjazebDepartment of Radiation Oncology, University of California Davis, Sacramento, CA 95817, USA.
William J MurphyDepartment of Dermatology, University of California Davis, Sacramento, CA 95817, USA.
Robert J CanterDivision of Surgical Oncology, Department of Surgery, University of California Davis, Sacramento, CA 95817, USA.ORCID 0000-0002-3331-5418
University of California, Davis · USStanford University · USUniversity of North Carolina at Chapel Hill · US

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI Laura Marcu · 2002 to 2026
$84.9M
UC Davis Paul Calabresi K12 Clinical Oncology Research Career Development ProgramK12CA138464 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI BIRKELAND, ANDREW CHARLES, LARA, PRIMO N. · 2011 to 2025
$11.4M
Radio-immunotherapy to Target Cancer Stem Cells in Solid Tumor MalignanciesR01CA189209 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI MURPHY, WILLIAM JOSEPH · 2015 to 2019
$2.0M
UC Davis Shared Astrios Cell SorterS10OD018223 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI SHACKLETT, BARBARA L. · 2015 to 2015
$555k
Shared LSRII Cytometer Equipment Application - UC Davis Stem Cell ProgramS10RR026825 · NCRR · UNIVERSITY OF CALIFORNIA AT DAVIS · PI NOLTA, JAN A. · 2010 to 2010
$500k
NCI NIH HHS K12 CA138464NCI NIH HHS P30 CA093373NCI NIH HHS R01 CA189209NCI NIH HHS S10 OD018223NCI NIH HHS S10 RR 026825NCRR NIH HHS S10 RR026825NIH HHS 1K12CA138464-01A2NIH HHS S10 OD018223
6 · The paper itself

Abstract

The cancer stem cell (CSC) hypothesis postulates that heterogeneous human cancers harbor a population of stem-like cells which are resistant to cytotoxic therapies, thus providing a reservoir of relapse following conventional therapies like chemotherapy and radiation (RT). CSCs have been observed in multiple human cancers, and their presence has been correlated with worse clinical outcomes. Here, we sought to evaluate the impact of drug dosing of the multi-tyrosine kinase inhibitor, sorafenib, on CSC and non-CSCs in soft tissue sarcoma (STS) models, hypothesizing differential effects of sorafenib based on dose and target cell population. In vitro, human cancer cell lines and primary STS from surgical specimens were exposed to escalating doses of sorafenib to determine cell viability and expression of CSC marker aldehyde dehydrogenase (ALDH). In vivo, ALDH

Indexed as

SarcomaTyrosine Kinase InhibitorsAldehyde DehydrogenaseCell Line, TumorHumansNeoplastic Stem CellsProtein Kinase InhibitorsSorafenibAldehyde DehydrogenaseProtein Kinase InhibitorsSorafenibTyrosine Kinase InhibitorsALDHcancer stem cellssarcomasorafenibsurvival

Identifiers

PMID38542325
PMCPMC10969893
OpenAlexW4392865177

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.